Research programme: antibacterials - Achaogen

Drug Profile

Research programme: antibacterials - Achaogen

Alternative Names: Achaogens; ACHN-978; LpxC inhibitors - Achaogen; SOS pathway inhibitors - Achaogen

Latest Information Update: 24 Jun 2016

Price : $50

At a glance

  • Originator Achaogen
  • Class Antibodies; Immunoglobulin fragments; Monoclonal antibodies; Peptides; Proteins; Small molecules
  • Mechanism of Action LpxC inhibitors; SOS response inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anthrax; Bacterial infections; Escherichia coli infections; Pseudomonal infections; Yersinia infections

Most Recent Events

  • 15 Mar 2016 Achaogen has patents pending for anti-pseudomonal LpxC inhibitor compounds in USA, Canada, China, Europe, Hong Kong, India, Japan, and Taiwan (Achaogen, Form 10-K, March 2016)
  • 15 Mar 2016 Achaogen announces intention to submit IND to US FDA in 2017
  • 01 Jan 2012 Preclinical trials in Escherichia coli infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top